您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Clonidine-d4(hydrochloride)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Clonidine-d4(hydrochloride)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Clonidine-d4(hydrochloride)图片
包装:2.5mg
规格:98%
市场价:6801元
分子量:270.6

产品介绍
An internal standard for the quantification of clonidine
货号:ajcx22106
CAS:67151-02-4
分子式:C9H5Cl2D4N3.HCl
分子量:270.6
溶解度:DMSO: slightly soluble,Methanol: slightly soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Clonidine-d4is intended for use as an internal standard for the quantification of clonidine by GC- or LC-MS. Clonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 61.66, 69.18, and 134.9 nM for α2A-, α2B-, and α2C-ARs, respectively).1It stimulates [35S]GTPγS binding to HEK293 cell membranes expressing the human receptors with EC50values of 26.92, 56.23, and 912.01 nM for α2A-, α2B-, and α2C-ARs, respectively. Clonidine also binds to I1-imidazoline sites in a variety of cell and tissue types (Kds = 4-15 nM).2It induces relaxation of isolated mesenteric artery rings precontracted with norepinephrine when used at a concentration of 10 μM.3Clonidine (10 μM) also induces membrane hyperpolarization and reduces norepinephrine-induced depolarization in isolated mesenteric artery rings. Clonidine (0.1 and 1 μg/kg) reduces mean blood pressure and heart rate when administeredviamicroinjection to the nucleus reticularis lateralis (NRL) of anesthetized normotensive cats.4Formulations containing clonidine have been used in the treatment of hypertension.


1.Jasper, J.R., Lesnick, J.D., Chang, L.K., et al.Ligand efficacy and potency at recombinant α2 adrenergic receptors: Agonist-mediated [35S]GTPγS bindingBiochem. Pharmacol.55(7)1035-1043(1998) 2.Ernsberger, P., Graves, M.E., Graff, L.M., et al.I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signalingAnn. N.Y. Acad. Sci. 763(1)22-42(1995) 3.Silva, E.G., Feres, T., Vianna, L.M., et al.Dual effect of clonidine on mesenteric artery adrenoceptors: Agonistic (alpha-2) and antagonistic (alpha-1)J. Pharmacol. Exp. Ther.277(2)872-876(1996) 4.Bousquet, P., Feldman, J., and Schwartz, J.Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolinesJ. Pharmacol. Exp. Ther.2301(1)232-236(1984)